Frost: Technological Innovations Expand Capabilities of Mass Spectrometers
September 30, 2008 // Published as a news service by IHS
| |
| Tools for Engineers |
IHS sells flexible standards collections and software to maximize your workflow. To learn more, and for a free quote, please complete the form below. |
|
| |
The acceptance of mass spectrometric techniques in research institutions across Europe is being driven by their inherent advantages, according to Frost & Sullivan, such as increased accuracy and higher throughput ratio.
Mass spectrometry (MS) has found significant use in the pharmaceutical and biotechnology sectors, where primary applications include the characterization of protein and other biologically active entities.
Recent analysis from Frost & Sullivan of the European mass spectrometry markets in basic research applications found earned revenues of $562 million in 2007, with estimates to reach $1078.8 million in 2014.
"In the field of environmental sciences, the analytical capabilities of MS platforms are extensively used in the identification of numerous toxins and pollutants," said Frost & Sullivan research analyst Suraj Ramanathan.
"The influence of this technology has reached areas such as forensic science. Further areas of interest include polymer analysis, environmental sciences, food safety and nutrition, drug abuse and rehabilitation, defense research and space research."
Analysts said the discovery of disease biomarkers has helped expand the capabilities of this analysis platform. The Fourier Transform Mass Spectrometry (FTMS) segment is showing maximum growth, with a high degree of technical innovation.
Many MS manufacturers have come out with customized research programs that suit end-user requirements. Analysts said this has led to numerous research and marketing agreements between MS manufacturers, companies and research organizations over a wide spectrum.
One of the most important challenges facing the European mass spectrometry markets, however, is the increase in strategic consolidations within the pharmaceutical industry.
Analysts said product pricing issues, changes in funding toward clinical research, funding from the private sector and reduced manpower for operating instruments are some of the other challenges confronting market participants.
"Compensating on logistical costs, many pharmaceutical companies have started outsourcing their R&D initiatives to countries such as India and China that are comparatively high on resources and manpower," said Ramanathan. "This reduces the need for high-tech instruments within Europe."
With end-users concerned about the shortage of skilled technicians to operate MS, manufacturers need to develop training programs to enable first-time users to familiarize themselves with the platform. Analysts said manufacturers could also regularly update end-users on technological advancements in the field of study with respect to MS usage.
This would aid them in applying MS in their research areas, thereby strengthening customer relationship.
Source: Frost & Sullivan.